[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Gene Therapy Market: 2019-2026 - Market Analysis and Forecast

November 2019 | 255 pages | ID: GBCD599E6295EN
BiotechForecasts

US$ 1,999.00

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
REPORT OVERVIEW:

Gene therapy has become one of the most rapidly growing and promising fields in regenerative medicine. As compared to conventional medicine, gene therapy is the single-dose solution for a wide application of diseases, significantly for genetic diseases, neurological, infectious and oncological disorders. Mainly encompasses the use of a viral vector to introduce an intact gene, either directly administered into the patient body (In-vivo) or indirectly via transduction of cells before infusion into the patient body (Ex-vivo), to reconstitute, remove, and modify a harmful gene variant.

The global gene therapy market was valued at $1,049 million in 2018, and is estimated to reach $10,443 million by 2026, registering a CAGR of 33.3% from 2018 to 2026.

Factors that drive the market growth involves, Increase in funding for R&D activities pertaining to gene therapy, For instance in 2018 cell and gene therapy companies raised over $981 Million in venture financing, Moreover in 2018 M&A volume reached to $18.8 Billion with a increase of 26% from 2017.

Increased in No. of Approved Products, By the end of Q3 2019 there are total 15 approved cell and gene therapy products, In 2017 FDA approves KYMRIAH®, YESCARTA® and LUXTURNA®, In 2019 ZOLGENSMA®, ZYNTEGLO® and COLLATEGENE® get market approval in U.S., EU and Japan respectively.

Other factors that boost the market growth involves; increase in government support, ethical acceptance of gene therapy for cancer treatment, rise in prevalence of cancer and increase in awareness regarding the gene therapy.

However, high cost associated with the treatment (KYMRIAH® cost around $475,000, and LUXTURNA® costs $425,000 per Eye) and unwanted immune responses are expected to hamper the market growth.

The report also presents detailed quantitative analysis of the current market trends and future estimations from 2018 to 2026.

The forecasts cover 2 Vector Type with 13 Sub categories, 8 Gene Type , 6 Application Type, 4 Regions and 16 Countries.

The report comes with an associated file covering quantitative data from all numeric forecasts presented in the report.

KEY FINDINGS:

The report has the following key findings:
  • The global gene therapy market accounted for $1,049 million in 2018 and is estimated to reach $10,443 million by 2026, registering a CAGR of 33.3% from 2018 to 2026.
  • The viral vector segment was valued at $566 million in 2018 and is estimated to reach $5264 million by 2026, registering a CAGR of 32.1% from 2018 to 2026.
  • Non-viral vector segment exhibits the highest growth rate in the forecast.
  • Antigen was the largest contributor among the gene type segments.
  • The oncological disorders segment currently holds 63% of market share and is expected to continue its dominance in future, follows by the rare disease segment.
  • North America dominated the global gene therapy market in 2018 and is projected to continue its dominance in the future.
  • China is expected to grow the highest in the Asia-Pacific region during the forecast period.
TOPICS COVERED:

The report covers the following topics:
  • Market drivers, restraints and opportunities
  • Porter's Five Forces Analysis
  • Top Winning Strategies, Top Investment Pockets
  • Analysis of By Vector Type, Gene Type, and Application Type
  • CAR T-Cell Applications, Limitations, and Market & Industry Tends
  • 50 Companies Profile, Product Portfolio, and Key Strategies
  • 15 Approved Cell and Gene Therapy Product Profiles
  • 30 gene therapy expected approvals in the phase III clinical trials
  • Gene Therapy clinical trials analysis from 1989 to 2018
  • Market analysis and forecasts from 2018 to 2026
FORECAST SEGMENTATION:

Market forecasts are provided for each of the following sub-markets and their categories:

1- By Vector Type
  • Viral vector
    • Adenoviruses
    • Lentiviruses
    • Adeno-Associated Virus
    • Retroviruses
    • Herpes Simplex Virus
    • Poxvirus
    • Vaccinia Virus
    • Others
  • Non-viral vector
    • Naked Plasmid Vectors
    • Electroporation
    • Gene Gun
    • Lipofection
    • Others
2- By Gene Type
  • Antigen
  • Cytokine
  • Tumor Suppressor
  • Suicide
  • Deficiency
  • Growth factors
  • Receptors
  • Others
3- By Application
  • Oncological Disorders
  • Rare Diseases
  • Cardiovascular Diseases
  • Neurological Disorders
  • Infectious disease
  • Other Diseases
4- By Region
  • North America: USA | Canada | Mexico
  • Europe: UK | Germany | France |Spain | Italy | Rest of Europe
  • Asia-Pacific: China | Japan | India |South Korea | Rest of Asia-Pacific
  • LAMEA: Brazil| South Africa | Rest of LAMEA
CHAPTER 1: INTRODUCTION

1.1 REPORT DESCRIPTION 17-18
1.2 TOPICS COVERED
1.3 KEY MARKET SEGMENTS
1.4 KEY BENEFITS
1.5 RESEARCH METHODOLOGY
1.6 TARGET AUDIENCE
1.7 COMPANIES MENTIONED 23-25

CHAPTER 2: EXECUTIVE SUMMARY

2.1 EXECUTIVE SUMMARY 26-28
2.2 CXO PROSPECTIVE

CHAPTER 3: MARKET OVERVIEW

3.1 MARKET DEFINITION AND SCOPE
3.2 KEY FINDINGS
3.3 TOP INVESTMENT POCKETS
3.4 TOP WINNING STRATEGIES
  3.4.1. Top winning strategies, by year, 2016-2018*
  3.4.2. Top winning strategies, by development, 2016-2018*(%)
  3.4.3. Top winning strategies, by company, 2016-2018*
3.5 TOP PLAYER POSITIONING, BY PIPELINE VOLUME, 2018
3.6 PORTERS FIVE FORCES ANALYSIS 37-38
3.7 MARKET DYNAMICS
  3.6.1 Drivers
    3.6.1.1 High investment for R&D activities pertaining to gene therapy
    3.6.1.2 Increase in prevalence of cancer
    3.6.1.3 Growth in awareness regarding gene therapy
  3.6.2 Restrains
    3.6.2.1 High cost associated with gene therapies
    3.6.2.2 Unwanted immune responses
  3.6.3 Opportunities
    3.6.3.1 Untapped potential for emerging markets

CHAPTER 4: GENE THERAPY APPROACH

4.1 OVERVIEW
4.2 IN VIVO APPROACH
4.3 EX VIVO APPROACH

CHAPTER 5: GENE THERAPY MARKET, BY VECTOR TYPE

5.1 OVERVIEW
  5.1.1 Market size and forecast
5.2 VIRAL VECTORS
  5.2.1 Key market trends
  5.2.2 Key growth factors and opportunities
  5.2.3 Market size and forecast 50-51
  5.2.4 Market size and forecast by country
  5.2.5 Adenovirus
  5.2.6 Lentivirus
  5.2.7 Adeno-Associated Virus
  5.2.8 Retrovirus
  5.2.9 Herpes Simplex Virus
  5.2.10 Poxvirus
  5.2.11 Vaccinia Virus
  5.2.12 Others 59-60
5.3 NON-VIRAL VECTORS
  5.3.1 Key market trends
  5.3.2 Key growth factors and opportunities
  5.3.3 Market size and forecast 62-63
  5.3.4 Market size and forecast by country
  5.3.5 Naked Plasmid Vector
  5.3.6 Electroporation 66-67
  5.3.7 Gene Gun
  5.3.8 Lipofection 69-70
  5.3.9 Others 71-72

CHAPTER 6: GENE THERAPY MARKET, BY GENE TYPE

6.1 OVERVIEW
  6.1.1 Market size and forecast 73-74
6.2 ANTIGEN
  6.2.1 Market size and forecast
  6.2.2 Market size and forecast by country
6.3 CYTOKINE 77-78
  6.3.1 Market size and forecast
  6.3.2 Market size and forecast by country
6.4 TUMOR SUPPRESSOR 80-82
  6.4.1 Market size and forecast
  6.4.2 Market size and forecast by country
6.5 SUICIDE 84-85
  6.5.1 Market size and forecast
  6.5.2 Market size and forecast by country
6.6 DEFICIENCY
  6.6.1 Market size and forecast
  6.6.2 Market size and forecast by country
6.7 GROWTH FACTORS 89-91
  6.7.1 Market size and forecast
  6.7.2 Market size and forecast by country
6.8 RECEPTORS
  6.8.1 CAR T-Cell and Gene Therapy
    6.8.3.1 Introduction and Process
    6.8.3.2 Applications and Limitations 94-95
    6.8.3.3 Approved Products and Clinical Trials
    6.8.3.4 Market and Industry Trends
  6.8.2 Market size and forecast
  6.8.3 Market size and forecast by country
6.9 OTHERS
  6.9.1 Market size and forecast
  6.9.2 Market size and forecast by country

CHAPTER 7: GENE THERAPY MARKET, BY APPLICATION

7.1 OVERVIEW
  7.1.1 Market size and forecast
7.2 ONCOLOGICAL DISORDERS 106-108
  7.2.1 Market size and forecast
  7.2.2 Market size and forecast by country
7.3 RARE DISEASES 110-114
  7.3.1 Market size and forecast
  7.3.2 Market size and forecast by country
7.4 CARDIOVASCULAR DISEASES
  7.4.1 Market size and forecast
  7.4.2 Market size and forecast by country
7.5 NEUROLOGICAL DISORDERS
  7.5.1 Market size and forecast
  7.5.2 Market size and forecast by country
7.6 INFECTIOUS DISEASE
  7.6.1 Market size and forecast
  7.6.2 Market size and forecast by country
7.7 OTHER DISEASES
  7.7.1 Market size and forecast
  7.7.2 Market size and forecast by country

CHAPTER 8: GENE THERAPY MARKET, BY REGION

8.1 OVERVIEW
  8.1.1 Market size and forecast
8.2 NORTH AMERICA
  8.2.1 Key market trends
  8.2.2 Key growth factors and opportunities
  8.2.3 Market size and forecast, by country
  8.2.4 Market size and forecast, by vector type
  8.2.5 Market size and forecast, by gene type
  8.2.6 Market size and forecast, by application
    8.2.6.1 U.S. market size and forecast, by vector type
    8.2.6.2 U.S. market size and forecast, by gene type
    8.2.6.3 U.S. market size and forecast, by application
    8.2.6.4 Canada market size and forecast, by vector type
    8.2.6.5 Canada market size and forecast, by gene type
    8.2.6.6 Canada market size and forecast, by application
    8.2.6.7 Mexico market size and forecast, by vector type
    8.2.6.8 Mexico market size and forecast, by gene type
    8.2.6.9 Mexico market size and forecast, by application
8.3 EUROPE
  8.4.1 Key market trends
  8.4.2 Key growth factors and opportunities
  8.4.3 Market size and forecast, by country
  8.4.4 Market size and forecast, by vector type
  8.4.5 Market size and forecast, by gene type
  8.4.6 Market size and forecast, by application
    8.3.6.1 Germany market size and forecast, by vector type
    8.3.6.2 Germany market size and forecast, by gene type
    8.3.6.3 Germany market size and forecast, by application
    8.3.6.4 France market size and forecast, by vector type
    8.3.6.5 France market size and forecast, by gene type
    8.3.6.6 France market size and forecast, by application
    8.3.6.7 UK market size and forecast, by vector type
    8.3.6.8 UK market size and forecast, by gene type
    8.3.6.9 UK market size and forecast, by application
    8.3.6.10 Italy market size and forecast, by vector type
    8.3.6.11 Italy market size and forecast, by gene type
    8.3.6.12 Italy market size and forecast, by application
    8.3.6.13 Spain market size and forecast, by vector type
    8.3.6.14 Spain market size and forecast, by gene type
    8.3.6.15 Spain market size and forecast, by application
    8.3.6.16 Rest of Europe market size and forecast, by vector type
    8.3.6.17 Rest of Europe market size and forecast, by gene type
    8.3.6.18 Rest of Europe market size and forecast, by application
8.4 ASIA-PACIFIC
  8.4.1 Key market trends
  8.4.2 Key growth factors and opportunities
  8.4.3 Market size and forecast, by country
  8.4.4 Market size and forecast, by vector type
  8.4.5 Market size and forecast, by gene type
  8.4.6 Market size and forecast, by application
    8.4.6.1 Japan market size and forecast, by vector type
    8.4.6.2 Japan market size and forecast, by gene type
    8.4.6.3 Japan market size and forecast, by application
    8.4.6.4 China market size and forecast, by vector type
    8.4.6.5 China market size and forecast by gene type
    8.4.6.6 China market size and forecast, by application
    8.4.6.7 India market size and forecast, by vector type
    8.4.6.8 India market size and forecast, by gene type
    8.4.6.9 India market size and forecast, by application
    8.4.6.10 South Korea market size and forecast, by vector type
    8.4.6.11 South Korea market size and forecast, by gene type
    8.4.6.12 South Korea market size and forecast, by application
    8.4.6.13 Rest of Asia-Pacific market size and forecast, by vector type
    8.4.6.14 Rest of Asia-Pacific market size and forecast, by gene type
    8.4.6.15 Rest of Asia-Pacific market size and forecast, by application
8.5 LAMEA
  8.5.1 Key market trends
  8.5.2 Key growth factors and opportunities
  8.5.3 Market size and forecast, by country
  8.5.4 Market size and forecast, by vector type
  8.5.5 Market size and forecast, by gene type
  8.5.6 Market size and forecast, by application
    8.5.6.1 Brazil market size and forecast by vector type
    8.5.6.2 Brazil market size and forecast, by gene type
    8.5.6.3 Brazil market size and forecast, by application
    8.5.6.4 South Africa market size and forecast, by vector type
    8.5.6.5 South Africa market size and forecast, by gene type
    8.5.6.6 South Africa market size and forecast, by application
    8.5.6.7 Rest of LAMEA market size and forecast by vector type
    8.5.6.8 Rest of LAMEA market size and forecast, by gene type
    8.5.6.9 Rest of LAMEA market size and forecast, by application

CHAPTER 9: CLINICAL TRIALS ANALYSIS & PRODUCT PROFILES

9.1 OVERVIEW
9.2 CLINICAL TRIALS FROM 1989 TO 2018
  9.2.1 Clinical Trials from 1989 to 2018: Based on Vector Type
  9.2.2 Clinical Trials from 1989 to 2018: Based on Gene Type
  9.2.3 Clinical Trials from 1989 to 2018: Based on Application
  9.2.4 Clinical Trials from 1989 to 2018: Based on Region
9.3 CLINICAL TRIALS IN 2019
9.4 EXPECTED APPROVALS AND PIPELINE 177-178
9.5 APPROVED PRODUCTS PROFILES
  9.5.1 GENDICINE
  9.5.2 ONCORINE
  9.5.3 REXIN-G
  9.5.4 NEOVASCULGEN
  9.5.5 GLYBERA
  9.5.6 IMLYGIC
  9.5.7 ZALMOXIS
  9.5.8 STRIMVELIS
  9.5.9 LUXTURNA
  9.5.10 KYMRIAH
  9.5.11 YESCARTA
  9.5.12 INVOSSA
  9.5.13 ZOLGENSMA
  9.5.14 ZYNTEGLO
  9.5.15 COLLATEGENE

CHAPTER 10: COMPANY PROFILES

10.1 KEY MARKET PLAYERS
  10.1.1. Adaptimmune Therapeutics Plc 187-188
  10.1.2. Abeona Therapeutics Inc. 189-190
  10.1.3. Adverum Biotechnologies, Inc. 191-192
  10.1.4. Applied Genetic Technologies Corporation 193-194
  10.1.5. Arbutus Biopharma Corporation 195-196
  10.1.6. Audentes Therapeutics Inc.
  10.1.7. Avexis Inc.
  10.1.8. Anchiano Therapeutics, Inc.
  10.1.9. Bluebird Bio, Inc. 200-201
  10.1.10. Celgene Corporation 202-203
  10.1.11. CRISPR Therapeutics AG
  10.1.12. Editas Medicine, Inc.
  10.1.13. Gilead Sciences, Inc. (Kite Pharma, Inc.) 206-207
  10.1.14. GlaxoSmithKline Plc 208-209
  10.1.15. Intellia Therapeutics Inc.
  10.1.16. Merck & Co., Inc. 211-212
  10.1.17. Novartis AG 213-214
  10.1.18. Regenxbio, Inc. 215-216
  10.1.19. Sangamo Therapeutics, Inc. 217-218
  10.1.20. Spark Therapeutics, Inc. 219-220
  10.1.21. Uniqure N.V. 221-222
  10.1.22. Voyager Therapeutics, Inc. 223-224
10.2 OTHER COMPANY PROFILES
  10.2.1. 4D Molecular Therapeutics
  10.2.2. Advantagene, Inc.
  10.2.3. Akouos, Inc.
  10.2.4. Allogene Therapeutics, Inc.
  10.2.5. Amgen, Inc
  10.2.6. American Gene Technologies International Inc.
  10.2.7. Amicus Therapeutics, Inc.
  10.2.8. Anges MG, Inc.
  10.2.9. Arrowhead Pharmaceuticals, Inc.
  10.2.10. Asklepios Biopharmaceutical, Inc.
  10.2.11. AstraZeneca Plc
  10.2.12. Atara Biotherapeutics, Inc.
  10.2.13. Avrobio, Inc.
  10.2.14. Bayer AG
  10.2.15. Benitec Biopharma Limited
  10.2.16. Biogen Inc.
  10.2.17. Biomarin Pharmaceutical, Inc.
  10.2.18. Bristol-Myers Squibb Company
  10.2.19. Carsgen Therapeutics, Ltd
  10.2.20. Casebia Therapeutics
  10.2.21. Cellectis SA
  10.2.22. Celyad SA
  10.2.23. Curevac AG
  10.2.24. Fibrocell Science Inc.
  10.2.25. Freeline Therapeutics, Ltd.
  10.2.26. Gensight Biologics S.A.
  10.2.27. Intrexon Corporation
  10.2.28. Oxford Biomedica Plc

CHAPTER 11: CONCLUSION & STRATEGIC RECOMMENDATIONS

11.1 STRATEGIC RECOMMENDATIONS 253-254
11.2 CONCLUSION

LIST OF TABLES

TABLE NO.1 LIST OF MENTIONED ORGANIZATIONS AND COMPANIES
TABLE NO.2 GENE THERAPY MARKET SCOPE
TABLE NO.3 GLOBAL GENE THERAPY MARKET BY VECTOR TYPE 2018-2026 ($MILLION)
TABLE NO.4 GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY REGION, 2018-2026 ($MILLION)
TABLE NO.5 GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE, 2018-2026 ($MILLION)
TABLE NO.6 VIRAL VECTOR CHARACTERISTICS
TABLE NO.7 GLOBAL GENE THERAPY MARKET FOR NON VIRAL VECTORS, BY REGION, 2018-2026 ($MILLION)
TABLE NO.8 GLOBAL GENE THERAPY MARKET FOR NON VIRAL VECTORS, BY TYPE, 2018-2026 ($MILLION)
TABLE NO.9 OVERVIEW OF DIFFERENT NON-VIRAL VECTOR DELIVERY
TABLE NO.10 GLOBAL GENE THERAPY, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.11 ANTIGEN GENE THERAPY MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE NO.12 CYTOKINES AS CANCER GENE THERAPY
TABLE NO.13 CYTOKINE GENE THERAPY MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE NO.14 TUMOR SUPPRESSOR BASED GENE THERAPY CANDIDATES
TABLE NO.15 TUMOR SUPPRESSOR GENES BY TYPES
TABLE NO.16 TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE NO.17 SUICIDE GENE THERAPY MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE NO.18 DEFICIENCY GENE THERAPY MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE NO.19 MAJOR GROWTH FACTOR FAMILIES, SOURCES AND ACTIONS
TABLE NO.20 GROWTH FACTORS GENE THERAPY MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE NO.21 RECEPTORS GENE THERAPY MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE NO.22 SUMMARY OF MAJOR ONCOLYTIC VIRUSES UNDER CLINICAL DEVELOPMENT
TABLE NO.23 LIST OF FEW DNA REPLICATION INHIBITORS
TABLE NO.24 GENE THERAPY MARKET FOR OTHER GENE TYPE, BY REGION, 2018-2026 ($MILLION)
TABLE NO.25 GLOBAL GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.26 LIST OF APPROVED GENE THERAPIES FOR CANCER
TABLE NO.27 LIST OF EXPECTED GENE THERAPY APPROVALS FOR CANCER INDICATIONS
TABLE NO.28 GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, BY REGION, 2018-2026 ($MILLION)
TABLE NO.29 LIST OF APPROVED GENE THERAPIES FOR RARE DISEASES
TABLE NO.30 LIST OF EXPECTED APPROVALS FOR RARE DISEASES INDICATIONS
TABLE NO.31 GENE THERAPY MARKET FOR RARE DISEASES, BY REGION, 2018-2026 ($MILLION)
TABLE NO.32 LIST OF EXPECTED GENE THERAPY APPROVALS FOR CARDIOVASCULAR DISEASES INDICATIONS
TABLE NO.33 GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2018-2026 ($MILLION)
TABLE NO.34 LIST OF EXPECTED GENE THERAPY APPROVALS FOR NEUROLOGICAL DISORDERS INDICATIONS
TABLE NO.35 GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2018-2026 ($MILLION)
TABLE NO.36 GENE THERAPY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018-2026 ($MILLION)
TABLE NO.37 LIST OF EXPECTED GENE THERAPY APPROVALS FOR DERMATOLOGICAL AND OPHTHALMOLOGICAL INDICATIONS
TABLE NO.38 GENE THERAPY MARKET FOR OTHER DISEASES, BY REGION, 2018-2026 ($MILLION)
TABLE NO.39 GENE THERAPY MARKET, BY REGION, 2018-2026 ($MILLION)
TABLE NO.40 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE NO.41 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.42 NORTH AMERICA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.43 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.44 U.S. GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.45 U.S. GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.46 U.S. GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.47 CANADA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.48 CANADA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.49 CANADA GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.50 MEXICO GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.51 MEXICO GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.52 MEXICO GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.53 EUROPE GENE THERAPY MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE NO.54 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.55 EUROPE GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.56 EUROPE GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.57 GERMANY GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.58 GERMANY GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.59 GERMANY GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.60 FRANCE GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.61 FRANCE GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.62 FRANCE GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.63 UK GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.64 UK GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.65 UK GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.66 ITALY GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.67 ITALY GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.68 ITALY GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.69 SPAIN GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.70 SPAIN GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.71 SPAIN GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.72 REST OF EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.73 REST OF EUROPE GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.74 REST OF EUROPE GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.75 ASIA-PACIFIC GENE THERAPY MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE NO.76 ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.77 ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.78 ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.79 JAPAN GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.80 JAPAN GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.81 JAPAN GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.82 CHINA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.83 CHINA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.84 CHINA GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.85 INDIA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.86 INDIA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.87 INDIA GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.88 SOUTH KOREA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.89 SOUTH KOREA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.90 SOUTH KOREA GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.91 REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.92 REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.93 REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.94 LAMEA GENE THERAPY MARKET, BY COUNTRY, 2018-2026 ($MILLION)
TABLE NO.95 LAMEA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.96 LAMEA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.97 LAMEA GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.98 BRAZIL GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.99 BRAZIL THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.100 BRAZIL GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.101 SOUTH AFRICA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.102 SOUTH AFRICA THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.103 SOUTH AFRICA GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.104 REST OF LAMEA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 ($MILLION)
TABLE NO.105 REST OF LAMEA THERAPY MARKET, BY GENE TYPE, 2018-2026 ($MILLION)
TABLE NO.106 REST OF LAMEA GENE THERAPY MARKET, BY APPLICATION, 2018-2026 ($MILLION)
TABLE NO.107 NUMBER OF CLINICAL TRIALS BASED ON VECTOR TYPE, 1989-2018
TABLE NO.108 NUMBER OF CLINICAL TRIALS BASED ON GENE TYPE, 1989-2018
TABLE NO.109 NUMBER OF CLINICAL TRIALS BASED ON APPLICATION, 1989-2018
TABLE NO.110 NUMBER OF CLINICAL TRIALS BASED ON REGION, 1989-2018
TABLE NO.111 BREAK DOWN OF 30, PHASE 3 CLINICAL TRIALS BASED ON INDICATION AREA, Q2 2019
TABLE NO.112 LIST OF 30 PHASE 3, GENE THERAPY CANDIDATES IN CLINICAL TRIALS, Q2 2019
TABLE NO.113 ADAPTIMMUNE THERAPEUTICS PLC.: COMPANY SNAPSHOT
TABLE NO.114 ADAPTIMMUNE THERAPEUTICS PLC.: BUSINESS UNIT
TABLE NO.115 ADAPTIMMUNE THERAPEUTICS PLC.: PRODUCT PORTFOLIO
TABLE NO.116 ABEONA THERAPEUTICS INC.: COMPANY SNAPSHOT
TABLE NO.117 ABEONA THERAPEUTICS INC.: PRODUCT CATEGORY
TABLE NO.118 ABEONA THERAPEUTICS INC.: PRODUCT PORTFOLIO
TABLE NO.119 ADVERUM BIOTECHNOLOGIES, INC.: COMPANY SNAPSHOT
TABLE NO.120 ADVERUM BIOTECHNOLOGIES, INC.: PRODUCT CATEGORY
TABLE NO.121 ADVERUM BIOTECHNOLOGIES, INC.: PRODUCT PORTFOLIO
TABLE NO.122 APPLIED GENETIC TECHNOLOGIES CORPORATION: COMPANY SNAPSHOT
TABLE NO.123 APPLIED GENETIC TECHNOLOGIES CORPORATION: OPERATING SEGMENTS
TABLE NO.124 APPLIED GENETIC TECHNOLOGIES CORPORATION: PRODUCT PORTFOLIO
TABLE NO.125 ARBUTUS BIOPHARMA CORPORATION: COMPANY SNAPSHOT
TABLE NO.126 ARBUTUS BIOPHARMA CORPORATION: PRODUCT PORTFOLIO
TABLE NO.127 AUDENTES THERAPEUTICS INC.: COMPANY SNAPSHOT
TABLE NO.128 AUDENTES THERAPEUTICS INC.: PRODUCT PORTFOLIO
TABLE NO.129 AVEXIS INC.: COMPANY SNAPSHOT
TABLE NO.130 AVEXIS INC.: PRODUCT PORTFOLIO
TABLE NO.131 ANCHIANO THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE NO.132 ANCHIANO THERAPEUTICS, INC.: PRODUCT CATEGORY
TABLE NO.133 ANCHIANO THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE NO.134 BLUEBIRD BIO, INC.: COMPANY SNAPSHOT
TABLE NO.135 BLUEBIRD BIO, INC.: PRODUCT CATEGORY
TABLE NO.136 BLUEBIRD BIO, INC.: PRODUCT PORTFOLIO
TABLE NO.137 CELGENE CORPORATION: COMPANY SNAPSHOT
TABLE NO.138 CELGENE CORPORATION: OPERATING SEGMENTS
TABLE NO.139 CELGENE CORPORATION: PRODUCT PORTFOLIO
TABLE NO.140 CRISPR THERAPEUTICS AG: COMPANY SNAPSHOT
TABLE NO.141 CRISPR THERAPEUTICS AG: PRODUCT PORTFOLIO
TABLE NO.142 EDITAS MEDICINE, INC.: COMPANY SNAPSHOT
TABLE NO.143 EDITAS MEDICINE, INC.: PRODUCT PORTFOLIO
TABLE NO.144 GILEAD SCIENCES. INC.: COMPANY SNAPSHOT
TABLE NO.145 GILEAD SCIENCES. INC.: OPERATING SEGMENTS
TABLE NO.146 GILEAD SCIENCES. INC.: PRODUCT PORTFOLIO
TABLE NO.147 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE NO.148 GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE NO.149 GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE NO.150 INTELLIA THERAPEUTICS INC.: COMPANY SNAPSHOT
TABLE NO.151 INTELLIA THERAPEUTICS INC.: PRODUCT PORTFOLIO
TABLE NO.152 MERCK & CO.,INC.: COMPANY SNAPSHOT
TABLE NO.153 MERCK & CO.,INC.: OPERATING SEGMENTS
TABLE NO.154 MERCK & CO.,INC.: PRODUCT PORTFOLIO
TABLE NO.155 NOVARTIS AG: COMPANY SNAPSHOT
TABLE NO.156 NOVARTIS AG: OPERATING SEGMENTS
TABLE NO.157 NOVARTIS AG: PRODUCT PORTFOLIO
TABLE NO.158 REGENXBIO, INC.: COMPANY SNAPSHOT
TABLE NO.159 REGENXBIO, INC.: PRODUCT PORTFOLIO
TABLE NO.160 SANGAMO THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE NO.161 SANGAMO THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE NO.162 SANGAMO THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE NO.163 SPARK THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE NO.164 SPARK THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE NO.165 SPARK THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE NO.166 UNIQURE N.V.: COMPANY SNAPSHOT
TABLE NO.167 UNIQURE N.V.: OPERATING SEGMENTS
TABLE NO.168 UNIQURE N.V.: PRODUCT PORTFOLIO
TABLE NO.169 VOYAGER THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE NO.170 VOYAGER THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE NO.171 VOYAGER THERAPEUTICS, INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE NO.1 GENE THERAPY MARKET SEGMENTS
FIGURE NO.2 GENE THERAPY CLINICAL TRIALS AT THE END OF Q2 2019
FIGURE NO.3 MERGERS AND ACQUISITIONS, BY VOLUME, 2016-2018*
FIGURE NO.4 TOP INVESTMENT POCKETS: BY GENE TYPE, 2018
FIGURE NO.5 BARGAINING POWER OF BUYERS
FIGURE NO.6 BARGAINING POWER OF SUPPLIERS
FIGURE NO.7 THREAT OF NEW ENTRANTS
FIGURE NO.8 THREAT OF SUBSTITUTION
FIGURE NO.9 COMPETITIVE RIVALRY
FIGURE NO.10 RESTRAINTS AND DRIVERS: GLOBAL GENE THERAPY
FIGURE NO.11 IN VIVO AND EX VIVO GENE THERAPY
FIGURE NO.12 SYSTEMATIC AND TARGETED IN VIVO APPROACH
FIGURE NO.13 EX-VIVO GENE THERAPY EXPLANATION
FIGURE NO.14 EX-VIVO VS IN-VIVO GENE THERAPY: BREAKDOWN OF PIPELINE, 2018
FIGURE NO.15 VIRAL VECTOR VS NON-VIRAL VECTOR: BREAKDOWN OF PIPELINE, 2018
FIGURE NO.16 GLOBAL GENE THERAPY MARKET TREND BY VECTOR TYPE 2018-2026 ($MILLION)
FIGURE NO.17 BREAKDOWN OF MARKET SHARE OF VIRAL VECTORS ON THE BASIS OF TYPE
FIGURE NO.18 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR VIRAL VECTORS, 2018 VS 2026 (%)
FIGURE NO.19 ADENOVIRUS STRUCTURE
FIGURE NO.20 RETROVIRUS VECTOR EDITING
FIGURE NO.21 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR NON VIRAL VECTORS, 2018 VS 2026 (%)
FIGURE NO.22 INOVIO'S ELECTROPORATION DEVICE CELECTRA
FIGURE NO.23 MECHANISM OF PLASMID DNA DELIVERY BY CELLECTRA
FIGURE NO.24 GLOBAL GENE THERAPY TREND, BY GENE TYPE, 2018-2026 ($MILLION)
FIGURE NO.25 COMPARATIVE REGIONAL SHARE ANALYSIS OF ANTIGEN GENE THERAPY MARKET, 2018 VS 2026 (%)
FIGURE NO.26 COMPARATIVE REGIONAL SHARE ANALYSIS OF CYTOKINE GENE THERAPY MARKET, 2018 VS 2026 (%)
FIGURE NO.27 COMPARATIVE REGIONAL SHARE ANALYSIS OF TUMOR SUPPRESSOR GENE THERAPY MARKET, 2018 VS 2026 (%)
FIGURE NO.28 COMPARATIVE REGIONAL SHARE ANALYSIS OF SUICIDE GENE THERAPY MARKET, 2018 VS 2026 (%)
FIGURE NO.29 COMPARATIVE REGIONAL SHARE ANALYSIS OF DEFICIENCY GENE THERAPY MARKET, 2018 VS 2026 (%)
FIGURE NO.30 COMPARATIVE REGIONAL SHARE ANALYSIS OF GROWTH FACTORS GENE THERAPY MARKET, 2018 VS 2026 (%)
FIGURE NO.31 INTRACELLULAR CELL SIGNALING
FIGURE NO.32 CAR T-CELL PROCESS
FIGURE NO.33 SHARE OF CAR T-CELL TRAILS TARGETING CD19, 2018
FIGURE NO.34 GLOBAL CAR T-CELL THERAPY CLINICAL TRIALS, BY NUMBERS, 2007-2018
FIGURE NO.35 GLOBAL DISTRIBUTION OF CAR T-CELL THERAPEUTIC COMPANIES, 2018
FIGURE NO.36 COMPARATIVE REGIONAL SHARE ANALYSIS OF RECEPTORS GENE THERAPY MARKET, 2018 VS 2026 (%)
FIGURE NO.37 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR OTHER GENE TYPE, 2018 VS 2026 (%)
FIGURE NO.38 BREAK DOWN OF GENE THERAPY CLINICAL TRIALS, BY DISEASE INDICATION, 2018
FIGURE NO.39 NO. OF GENE THERAPY CLINICAL TRIALS, BY CANCER TYPES, 2018
FIGURE NO.40 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, 2018 VS 2026
FIGURE NO.41 GENE THERAPY CLINICAL TRAILS BREAK DOWN, BY RARE DISEASES, 2018
FIGURE NO.42 BREAK DOWN OF RARE DISEASE CLINICAL TRIALS, BY DISEASE INDICATION, 2018
FIGURE NO.43 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR RARE DISEASES, 2018 VS 2026 (%)
FIGURE NO.44 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, 2018 VS 2026 (%)
FIGURE NO.45 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, 2018 VS 2026
FIGURE NO.46 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR INFECTIOUS DISEASES, 2018 VS 2026 (%)
FIGURE NO.47 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR OTHER DISEASES, 2018 VS 2026 (%)
FIGURE NO.48 GENE THERAPY CLINICAL TRIALS APPROVED WORLDWIDE FROM 1989-2018
FIGURE NO.49 COMPARISON OF VIRAL VS NON VIRAL CLINICAL TRIALS , 1989-2018
FIGURE NO.50 CLINICAL TRIALS BASED ON GENE TYPE, 1989-2018
FIGURE NO.51 CLINICAL TRIALS BASED ON APPLICATION, 1989-2018
FIGURE NO.52 CLINICAL TRIALS BASED ON REGION, 1989-2018
FIGURE NO.53 GENE THERAPY CLINICAL TRIALS AT THE END OF Q2 2019
FIGURE NO.54 ADAPTIMMUNE THERAPEUTICS PLC.: REVENUE, 2016-2018 ($MILLION)
FIGURE NO.55 ABEONA THERAPEUTICS INC.: REVENUE, 2016-2018 ($MILLION)
FIGURE NO.56 ADVERUM BIOTECHNOLOGIES, INC.: REVENUE, 2016-2018 ($MILLION)
FIGURE NO.57 AGTC: REVENUE, 2016-2018 ($MILLION)
FIGURE NO.58 ARBUTUS BIOPHARMA CORPORATION.: REVENUE, 2016-2018 ($MILLION)
FIGURE NO.59 BLUEBIRD BIO, INC.: REVENUE, 2016-2018 ($MILLION)
FIGURE NO.60 CELGENE CORPORATION: REVENUE, 2016-2018 ($MILLION)
FIGURE NO.61 GILEAD SCIENCES. INC.: REVENUE, 2016-2018 ($MILLION)
FIGURE NO.62 GILEAD SCIENCES. INC.: REVENUE, BY GEOGRAPHY 2018 (%)
FIGURE NO.63 GSK PLC: REVENUE, 2016-2018 ($MILLION)
FIGURE NO.64 GSK PLC: REVENUE BY GEOGRAPHY AND PRODUCT SEGMENT 2018 (%)
FIGURE NO.65 MERCK & CO.,INC.: REVENUE, 2016-2018 ($MILLION)
FIGURE NO.66 MERCK & CO.,INC.:REVENUE BY GEOGRAPHY & PRODUCT SEGMENT 2018(%)
FIGURE NO.67 NOVARTIS AG: REVENUE, 2016-2018 ($MILLION)
FIGURE NO.68 NOVARTIS AG: REVENUE BY GEOGRAPHY AND PRODUCT SEGMENT 2018 (%)
FIGURE NO.69 REGENXBIO, INC.: REVENUE, 2016-2018 ($MILLION)
FIGURE NO.70 SANGAMO THERAPEUTICS, INC.: REVENUE, 2016-2018 ($MILLION)
FIGURE NO.71 SPARK THERAPEUTICS, INC.: REVENUE, 2016-2018 ($MILLION)
FIGURE NO.72 UNIQURE N.V.: REVENUE, 2016-2018 ($MILLION)
FIGURE NO.73 VOYAGER THERAPEUTICS, INC.: REVENUE, 2016-2018 ($MILLION)


More Publications